Daraxonrasib, a pan-RAS inhibitor, selectively inhibits osteosarcomas with activated KRAS by halting AKT signaling and matrix metalloprotease activity.
Saved in:
| Title: | Daraxonrasib, a pan-RAS inhibitor, selectively inhibits osteosarcomas with activated KRAS by halting AKT signaling and matrix metalloprotease activity. |
|---|---|
| Authors: | Jung, Okkeun1,2 (AUTHOR), Soto, Angelene3 (AUTHOR), Wolfe, Andrew L.2,3,4,5,6 (AUTHOR) awolfe@genectr.hunter.cuny.edu, Mahajan, Shahana S.1,2,3,5,7 (AUTHOR) smahajan@hunter.cuny.edu |
| Source: | PLoS ONE. 8/8/2025, Vol. 20 Issue 8, p1-15. 15p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
